- Status:
- Red
- Decision Date:
- None
Comments
RED: Monotherapy for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 R132 mutation who were previously treated by at least one prior line of systemic therapy. (Decision date - Sep 2023)
RED: Use in combination with azacitidine for the treatment of adults with newly diagnosed acute myeloid leukaemia with an isocitrate dehydrogenase-1 R132 mutation who are not eligible to receive standard induction chemotherapy. (Decision date - Sep 2023)
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
- 8. NHS England commissioned – to be used in line with NHSE commissioning intentions
search again
